Coeptis Therapeutics (COEP)
Nasdaq-listed Coeptis developed cell therapy assets before its Z Squared merger.
Something off on this page? Send us feedback.
COEP was the Nasdaq symbol for Coeptis Therapeutics Holdings, a small biopharmaceutical and technology company developing cell therapy platforms for cancer, autoimmune and infectious diseases. The issuer completed a reverse merger with Z Squared in April 2026 and changed its name and symbol to ZSQR.
Coeptis Therapeutics Holdings was a Nasdaq-listed micro-cap operating company with biotechnology and technology segments. Its biotechnology work centered on licensed or partnered cell therapy platforms, including DVX201, an unmodified natural killer cell therapy technology, SNAP-CAR from the University of Pittsburgh, and GEAR, a gene-edited antibody resistant cell therapy platform advanced through GEAR Therapeutics.
Its technology segment came from the NexGenAI Affiliates Network asset purchase and provided AI-enabled marketing automation, lead generation, content marketing, analytics, and related managed services. The company reported no commercial capability for approved drug sales and relied on partnerships for future commercialization. In April 2026, Coeptis completed a business combination with Z Squared, spun out most biopharmaceutical operations to stockholders, and the listed issuer changed its name and trading symbol to Z Squared and ZSQR.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $15.5M · Total debt $0 · Total assets $134.5M · Shareholders' equity $132.5M
- Revenue
- $1.6M
- Operating income
- −$13.8M
- Net income
- −$13.7M
No dividends on record.
| Institutions45 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 12.70% | 6.73M shares | |
| Insiders9 holders · as of Feb 13, 2026 | 1.69% | 896.0K shares | |
| Otherremainder | ≈ 85.61% | 45.37M shares |
53.00M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (53.00M in the company's Sep 3, 2026 report, 3.51M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
BlackRock, Inc.Institution | 4.76% | 2.52M | 13Fas of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.15% | 1.67M | 13Fas of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 1.35% | 713,196 | 13Fas of Jun 30, 2026 |
Chris CaliseInsiderdirector | 0.70% | 368,741 | Form 4filed Feb 13, 2026 ↗ |
Northern Trust CorpInstitution | 0.65% | 346,687 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
Not reported.